Schedule 13D ownership disclosure

Adamis Pharmaceuticals Corp

Security class unavailable · CUSIP: 00547W208

Event date: 2023-05-25

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
288,824
Percent of class
9.9900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001839882-23-014903
Form type
SC 13D
Filer
DMK PHARMACEUTICALS Corp
CIK
CIK 887247
Filed
Jun 05, 2023
Reporting period
May 25, 2023
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub